Enrico Martin

84 Chapter 4 31. Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys . 1998;42(2):351-360. 32. Kroep JR, Ouali M, Gelderblom H, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol Off J Eur Soc Med Oncol . 2011;22(1):207-214. doi:10.1093/annonc/mdq338 33. Higham CS, Steinberg SM, Dombi E, et al. SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. Sarcoma . 2017;2017:8685638. doi:10.1155/2017/8685638 34. Miao R, Wang H, Jacobson A , et al. Radiation -induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST. Radiother Oncol . 2019;137:61-70. doi:10.1016/j.radonc.2019.03.015 35. Porter DE, Prasad V, Foster L, Dall GF, Birch R, Grimer RJ. Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours. Sarcoma . 2009;2009:756395. doi:10.1155/2009/756395 36. Brekke HR, Kolberg M, Skotheim RI, et al. Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. Neuro Oncol . 2009;11(5):514-528. doi:10.1215/15228517-2008-127 37. Yuan ZN, Xu LB, Zhao ZG, et al. Clinicopathological features and prognosis of malignant peripheral nerve sheath tumor: a retrospective study of 159 cases from 1999 to 2016. Oncotarget . 2017;8(62):104785-104795. doi:10.18632/ oncotarget.18975 38. Cleven AHG, Sannaa GA Al, Briaire- de Bruijn I, et al. Loss of H3K27 tri- methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol . 2016;29(6):582-590. doi:10.1038/modpathol.2016.45 39. LaFemina J, Qin L-X, Moraco NH, et al. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors. Ann Surg Oncol . 2013;20(1):66-72. doi:10.1245/s10434-012- 2573-2 40. Bates JE, Peterson CR, Dhakal S, Giampoli EJ, Constine LS. Malignant peripheral nerve sheath tumors (MPNST): A SEER analysis of incidence across the age spectrum and therapeutic interventions in the pediatric population. Pediatr Blood Cancer . 2014;61(11):1955-1960. doi:10.1002/pbc.25149 41. Neville H, Corpron C, Blakely ML, Andrassy R. Pediatric neurofibrosarcoma. J Pediatr Surg . 2003;38(3):343-346. doi:10.1053/ jpsu.2003.50105 42. Ferrari A, Bisogno G, Carli M. Management of childhood malignant peripheral nerve sheath tumor. Paediatr Drugs . 2007;9(4):239-248. 43. Gerrand CH, Wunder JS, Kandel RA, et al. Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence. J Bone Joint Surg Br . 2001;83(8):1149-1155. 44. Clarkson PW, Griffin AM, Catton CN, et al. Epineural dissection is a safe technique that facilitates limb salvage surgery. Clin Orthop Relat Res . 2005;438:92-96. 45. O’Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet (London, England) . 2002;359(9325):2235-2241. doi:10.1016/S0140-6736(02)09292-9